Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388694 · ClinicalTrials.gov registry record · NA
Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests
A NA study of Attention Deficit Hyper Activity, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
- 1
- Study location
NCT06388694: Completed NA study of Attention Deficit Hyper Activity, sponsored by Kaiser Permanente.
NCT06388694 is a NA study of Attention Deficit Hyper Activity that has completed, run by Kaiser Permanente. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388694, a NA study of Attention Deficit Hyper Activity, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
- 1
- Study location
Study Summary
This cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience.
Primary Outcome
Percentage of participants referred for a follow-up visit for a weight check, among those who had not had a weight check in the 6 months prior to the medication refill request
Conditions Studied
Interventions
- OTHER Pharmacist Care
- OTHER Primary Care Physician Care
Study Locations (1)
California
- Kaiser Permanente Northern California - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2024-05-06 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT06388694 record still lists
NCT06388694 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Attention Deficit Hyper Activity appearing as the primary indexed condition, and to 2 interventions - of which Pharmacist Care is the first listed.
NCT06388694 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06388694 about?
NCT06388694 is a clinical study titled "Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests". This cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience.
What is the current status of trial NCT06388694?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2024-05-06. Estimated completion is 2024-07-31.
What conditions does trial NCT06388694 study?
This clinical trial studies the following conditions: Attention Deficit Hyper Activity.
What interventions are being tested in trial NCT06388694?
The interventions under investigation include: Pharmacist Care (OTHER), Primary Care Physician Care (OTHER).
Who is sponsoring clinical trial NCT06388694?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388694 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyper Activity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06388694's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI